Financing ·
Jupiter Neurosciences, Inc. entered into a Securities Purchase Agreement on August 21, 2026, to sell 307,692 shares of…
JUNSJupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. entered into a Securities Purchase Agreement on August 21, 2026, to sell 307,692 shares of common stock in a registered direct offering at $6.50 per share, generating approximately $2.0 million in gross proceeds before fees and expenses. The transaction is expected to close around August 24, 2026, with D. Boral Capital LLC acting as the placement agent for a 7.0% fee plus reimbursable expenses up to $75,000. Additionally, between August 14 and August 21, 2026, the company issued 107,920 shares to YA II PN, Ltd. under its Standby Equity Purchase Agreement for aggregate gross proceeds of $851,194. Jupiter Neurosciences is a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation.